Acuity Inc. shares rise 1.15% premarket after Oculis reports positive Q2 2025 financial results and pipeline advancements.

Acuity Inc. rose 1.15% in premarket trading. The company's stock price increase may be attributed to the recent news about Oculis, which is preparing to initiate a Phase 2/3 trial for Privosegtor in acute optic neuritis and expanding clinical development into two new indications. This news is positive for the stock as it indicates progress in the company's pipeline and potential new treatments.